Form 4: Metagenomi CFO Reports RSU Grant, Tax-Related Stock Sale

Metagenomi's Chief Financial Officer, Pamela Wapnick, reported the acquisition of 120,000 restricted stock units and a tax-related sale of 1,576 common shares.

Summary

• Pamela Wapnick, Metagenomi's Chief Financial Officer, reported two transactions involving the company's common stock.
• On September 5, 2025, 1,576 shares of common stock were sold at a price of $1.81 per share. This sale was non-volitional and conducted solely to satisfy tax withholding obligations upon the vesting of previously granted restricted stock units (RSUs).
• Following this tax-related sale, Ms. Wapnick's direct beneficial ownership of common stock was 70,532 shares.
• On December 1, 2025, Ms. Wapnick acquired 120,000 restricted stock units (RSUs) at a reported value of $1.6 per unit.
• These newly acquired RSUs are subject to a vesting schedule: 50% will vest on December 5, 2026, and the remaining 50% will vest on December 5, 2027, contingent upon Ms. Wapnick's continued service with Metagenomi.
• After the RSU acquisition, Ms. Wapnick's direct beneficial ownership of common stock increased to 190,532 shares.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation and tax obligations, which are neutral in sentiment. The RSU grant is a positive for executive retention, while the tax-related sale is a standard occurrence.

Positives

• The acquisition of 120,000 restricted stock units (RSUs) aligns the Chief Financial Officer's interests with the long-term performance of Metagenomi.
• The multi-year vesting schedule for the RSUs, extending to December 2027, indicates a commitment from the CFO to continued service with the company.

Negatives

• A sale of 1,576 shares, even if for tax purposes, results in a reduction of the CFO's direct common stock holdings.

Risks

• The vesting of the 120,000 restricted stock units is contingent upon the Chief Financial Officer's continued service with Metagenomi, posing a risk if her employment terminates before the specified vesting dates.

Future Outlook

The Chief Financial Officer's future compensation is tied to Metagenomi's performance and her continued service through December 2027, as indicated by the vesting schedule of the newly acquired restricted stock units.

Industry Context

This is a routine insider transaction filing, common across all publicly traded companies, reflecting executive compensation and tax management practices rather than specific industry trends.

Stakeholder Impact

• Shareholders: The increase in the CFO's beneficial ownership through RSUs aligns her interests with long-term shareholder value, while the small tax-related sale is negligible.
• Employees: The RSU grant is part of standard executive compensation, which can set a precedent for other employee equity programs.

Next Steps

• Vesting of 50% of the 120,000 restricted stock units on December 5, 2026.
• Vesting of the remaining 50% of the 120,000 restricted stock units on December 5, 2027.

Key Dates

Keywords

Metagenomi, MGX, Form 4, Insider Transaction, Restricted Stock Units, CFO, Stock Sale, Equity Compensation